Literature DB >> 20682144

Safety of contraceptive methods for women with rheumatoid arthritis: a systematic review.

Sherry L Farr1, Suzanne G Folger, Melissa E Paulen, Kathryn M Curtis.   

Abstract

BACKGROUND: Women with rheumatoid arthritis (RA) and their clinicians may have unique concerns about certain methods of contraception. STUDY
DESIGN: We conducted a systematic review of the literature in the MEDLINE database through February 2009 for peer-reviewed journal articles on use of any method of contraception, or progestins or estrogens, and progression of RA.
RESULTS: We identified eight articles that met the inclusion criteria: six examined oral contraceptives (OCs), one progesterone, and one estrogen. We found no studies on other methods of contraception. For OCs, no consistent pattern of improvement or worsening of disease emerged and most patients showed little change in RA symptoms. We saw little improvement in the studies examining progesterone and estrogen.
CONCLUSION: Although sparse and based primarily on older studies of poor quality, this information suggests that OC use is unlikely to affect RA disease progression. Research is needed on other forms of contraception, such as DMPA and IUD. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20682144     DOI: 10.1016/j.contraception.2010.02.003

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  "It Would Have Been Nice to Have a Choice": Barriers to Contraceptive Decision-making among Women with Disabilities.

Authors:  Willi Horner-Johnson; Krystal A Klein; Jan Campbell; Jeanne-Marie Guise
Journal:  Womens Health Issues       Date:  2022-02-09

2.  Establishing cross-discipline consensus on contraception, pregnancy and breast feeding-related educational messages and clinical practices to support women with rheumatoid arthritis: an Australian Delphi study.

Authors:  Andrew M Briggs; Joanne E Jordan; Ilana N Ackerman; Sharon Van Doornum
Journal:  BMJ Open       Date:  2016-09-15       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.